PATH EX is a technology company.
PATH EX has raised $645K across 2 funding rounds.
PATH EX has raised $645K in total across 2 funding rounds.
PATH EX has raised $645K in total across 2 funding rounds.
PATH EX's investors include .406 Ventures, Innova Memphis.
PATH EX is a medical device company developing investigational extracorporeal blood cleansing technologies to diagnose and treat sepsis and bacteremia by selectively removing pathogens and endotoxins from the bloodstream.[1][2][4] Its flagship product, CycloPE®, rapidly reduces bacterial load by over 95% in a single pass through the device, targeting healthcare providers managing critical infections in intensive care settings.[3][4] Founded in 2016 and headquartered in Nashville, Tennessee (with operations in Houston's Texas Medical Center), PATH EX has raised $7.2M total, including a recent $5M Series A round in May 2025 led by IAG Capital Partners to fund clinical trials, FDA submission, and commercialization.[1][3]
The company solves the urgent problem of sepsis—a leading cause of hospital deaths—by addressing the root cause through direct pathogen removal rather than symptom management alone, with early clinical data showing improved patient biomarkers.[3][4][6] This positions PATH EX for growth amid rising antimicrobial resistance, as its devices enable faster microbial identification without culturing.[2][4]
PATH EX was founded in 2016 in Nashville, Tennessee, initially focusing on investigational medical devices for sepsis treatment and diagnosis.[1][2] The company's idea emerged from the need for rapid blood purification to combat pathogens and endotoxins, building on technologies like analytical chemistry, biotechnology, and chromatography, as evidenced by its two filed patents.[1]
Key early traction includes NSF-backed studies demonstrating over 95% bacteria reduction in bloodstream models, validating the core technology.[4] By 2025, PATH EX relocated key operations to Houston's Texas Medical Center Innovation Factory, appointed Sinead Miller as CEO, and secured a pivotal $5M financing round in May—led by IAG Capital Partners with TMC Venture Fund and Fitz Gate Ventures support—following compelling clinical data on CycloPE®.[3] This funding marks a turning point, adding board member Jeff Burbank with 30+ years in medical device development.[3]
PATH EX stands out in sepsis care through these key strengths:
These features make PATH EX's platform faster, more precise, and ecosystem-ready for ICUs.
PATH EX rides the sepsis treatment revolution, where annual U.S. deaths exceed 350,000 amid surging antimicrobial resistance and aging populations driving hospital infections.[3][4] Timing is critical: post-pandemic awareness of rapid diagnostics and blood purification (e.g., similar to CytoSorb tech) favors adjunct therapies like CycloPE®, which could cut mortality by enabling immediate intervention.[1][4]
Market forces include FDA push for breakthrough devices, venture interest in medtech (evident in its Series A), and hospital demands for tools reducing ICU stays.[3] PATH EX influences the ecosystem by advancing extracorporeal tech, potentially integrating with AI-driven monitoring, and inspiring pathogen-agnostic platforms amid global superbug threats.[2][5]
PATH EX is poised for FDA clearance and first commercial sales post-2025 trials, leveraging $5M to scale manufacturing and operations.[3] Rising sepsis incidence and resistance trends will propel adoption, especially if CycloPE® proves mortality benefits in larger studies. Its influence may expand via partnerships with device giants (e.g., akin to Baxter's Cheetah acquisition), solidifying PATH EX as a sepsis standard.[1][3]
This builds on its core promise: turning seconds into survival by cleansing blood of sepsis's root cause.[4][6]
PATH EX has raised $645K across 2 funding rounds. Most recently, it raised $620K Seed in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $620K Seed | .406 Ventures, Innova Memphis | |
| Jan 1, 2018 | $25K Seed | .406 Ventures, Innova Memphis |